OppenheimerFunds Inc. grew its stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 14.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,644,596 shares of the medical equipment provider’s stock after purchasing an additional 340,845 shares during the quarter. OppenheimerFunds Inc. owned approximately 1.31% of Zimmer Biomet worth $319,124,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently modified their holdings of the company. Longview Partners Guernsey LTD raised its position in shares of Zimmer Biomet by 6.9% in the fourth quarter. Longview Partners Guernsey LTD now owns 8,027,808 shares of the medical equipment provider’s stock valued at $968,716,000 after purchasing an additional 521,124 shares during the period. Nordea Investment Management AB raised its position in shares of Zimmer Biomet by 7.3% in the third quarter. Nordea Investment Management AB now owns 5,277,660 shares of the medical equipment provider’s stock valued at $617,961,000 after purchasing an additional 357,302 shares during the period. American Century Companies Inc. raised its position in shares of Zimmer Biomet by 14.7% in the fourth quarter. American Century Companies Inc. now owns 4,777,397 shares of the medical equipment provider’s stock valued at $576,488,000 after purchasing an additional 612,044 shares during the period. Jana Partners LLC raised its position in shares of Zimmer Biomet by 16.6% in the third quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock valued at $545,932,000 after purchasing an additional 662,497 shares during the period. Finally, Bank of New York Mellon Corp raised its position in shares of Zimmer Biomet by 24.4% in the third quarter. Bank of New York Mellon Corp now owns 2,759,704 shares of the medical equipment provider’s stock valued at $323,134,000 after purchasing an additional 541,102 shares during the period. 88.18% of the stock is currently owned by institutional investors.
Several equities analysts have recently weighed in on the stock. Goldman Sachs Group raised shares of Zimmer Biomet from a “sell” rating to a “neutral” rating and set a $125.00 price objective on the stock in a research report on Tuesday, December 19th. Stifel Nicolaus upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating and upped their price target for the company from $120.00 to $168.00 in a research note on Wednesday, January 31st. Canaccord Genuity restated a “hold” rating and issued a $132.00 price target on shares of Zimmer Biomet in a research note on Friday, January 5th. Robert W. Baird restated a “buy” rating on shares of Zimmer Biomet in a research note on Wednesday, January 31st. Finally, BMO Capital Markets restated a “buy” rating and issued a $142.00 price target on shares of Zimmer Biomet in a research note on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $141.67.
Shares of Zimmer Biomet Holdings Inc (ZBH) opened at $118.72 on Wednesday. The stock has a market cap of $24,393.96, a PE ratio of 15.00, a price-to-earnings-growth ratio of 2.12 and a beta of 1.08. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.83 and a current ratio of 1.52. Zimmer Biomet Holdings Inc has a one year low of $108.03 and a one year high of $133.49.
Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.10. The firm had revenue of $2.07 billion for the quarter, compared to the consensus estimate of $2.03 billion. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the prior year, the company posted $2.14 earnings per share. equities analysts predict that Zimmer Biomet Holdings Inc will post 7.82 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Monday, January 29th. Shareholders of record on Friday, December 29th were paid a dividend of $0.24 per share. The ex-dividend date was Thursday, December 28th. This represents a $0.96 dividend on an annualized basis and a yield of 0.81%. Zimmer Biomet’s payout ratio is 10.65%.
In other Zimmer Biomet news, VP Chad F. Phipps sold 20,826 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $115.95, for a total transaction of $2,414,774.70. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Bryan C. Hanson acquired 25,077 shares of Zimmer Biomet stock in a transaction on Tuesday, February 20th. The shares were purchased at an average price of $119.68 per share, for a total transaction of $3,001,215.36. The disclosure for this purchase can be found here. Corporate insiders own 1.07% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.thelincolnianonline.com/2018/02/21/zimmer-biomet-holdings-inc-zbh-shares-bought-by-oppenheimerfunds-inc.html.
Zimmer Biomet Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.